You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Colorectal cancer

Panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer (terminated appraisal)

  • Technology appraisal
  • Reference number: TA240
  • Published:  14 December 2011
  • Last updated:  29 March 2017
  • Guidance
  • Tools and resources
  • History

On this page

  1. Background information
  2. Colorectal cancer (metastatic) - panitumumab: letter to stakeholders about suspension

History

A list of downloadable documents created during development.

Background information

  • Review decision - March 2015 information

  • Appendix A - RPP decision paper March 2015 (PDF 72 KB)

    Published:
    25 March 2015
  • Colorectal cancer (metastatic) - panitumumab (terminated appraisal): review proposal 9 February 2015 information

  • Colorectal cancer (metastatic)- panitumumab (terminated appraisal): appendix A matrix of stakeholders (PDF 101 KB)

    Published:
    09 February 2015
  • Colorectal cancer (metastatic)- panitumumab (terminated appraisal): appendix B - GE proposal paper January 2015 (PDF 621 KB)

    Published:
    09 February 2015
  • TA176 Colorectal cancer (first line) - cetuximab and TA240 Colorectal cancer (metastatic) - panitumumab (terminated appraisal): review decision - January 2014 information

  • TA176 and TA240; Cetuximab and Panitumumab for the first-line treatment of metastatic colorectal cancer: appendix A - GE Decision Paper - January 2014 (PDF 230 KB)

    Published:
    27 January 2014

Colorectal cancer (metastatic) - panitumumab: letter to stakeholders about suspension

  • Colorectal cancer (metastatic) - panitumumab: letter to stakeholders about suspension (PDF 10 KB)

    Published:
    30 August 2011